Hurdles toward a cure for CML: the CML stem cell.

@article{Gallipoli2011HurdlesTA,
  title={Hurdles toward a cure for CML: the CML stem cell.},
  author={Paolo Gallipoli and Sheela Abraham and Tessa L. Holyoake},
  journal={Hematology/oncology clinics of North America},
  year={2011},
  volume={25 5},
  pages={
          951-66, v
        }
}
Chronic myeloid leukemia (CML) is the first cancer in which a genetic alteration was proven to be of pathogenic significance and is considered a disease model for oncogene addiction, targeted therapy, and cancer stem cells (CSCs). The introduction of tyrosine kinase inhibitors (TKIs) resulted in dramatic improvement in response and survival for patients with CML in chronic phase (CP); however, CSCs are spared by TKIs. In this article, we review the role of CSCs in CML in CP, their persistence… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

Discontinuation of tyrosine kinase therapy in CML

  • Annals of Hematology
  • 2015
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED